A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Cell Res. 2020 Oct;30(10):932-935. doi: 10.1038/s41422-020-0387-5. Epub 2020 Aug 5.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / immunology
  • Betacoronavirus / chemistry
  • Betacoronavirus / genetics*
  • Betacoronavirus / immunology
  • COVID-19
  • COVID-19 Vaccines
  • Cell Line
  • Coronavirus Infections / genetics
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control*
  • Gene Expression
  • Humans
  • Immunization
  • Mice, Inbred BALB C
  • Pandemics / prevention & control*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control*
  • Protein Domains
  • RNA, Messenger / genetics
  • RNA, Messenger / pharmacology
  • RNA, Messenger / therapeutic use*
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / chemistry
  • Spike Glycoprotein, Coronavirus / genetics*
  • Spike Glycoprotein, Coronavirus / immunology
  • Viral Vaccines / genetics
  • Viral Vaccines / pharmacology
  • Viral Vaccines / therapeutic use*

Substances

  • Antibodies, Neutralizing
  • COVID-19 Vaccines
  • RNA, Messenger
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines
  • spike protein, SARS-CoV-2